Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma.

Trial Profile

Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Enzastaurin (Primary) ; Lomustine
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms STEERING
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Mar 2012 Planned end date changed from 1 Apr 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Planned end date changed from Apr 2010 to Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top